Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis

Future Microbiol. 2015;10(6):1077-99. doi: 10.2217/fmb.15.9.

Abstract

Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) was first described almost two decades ago. We undertook this systematic review and meta-analysis to collate findings across studies that have reported the incidence, clinical features, management and outcomes of paradoxical TB-IRIS. Forty studies that cumulatively reported 1048 paradoxical TB-IRIS cases were included. The pooled estimated incidence among patients with HIV-associated TB initiating antiretroviral therapy was 18% (95% CI: 16-21%). Frequent features were pulmonary and lymph node involvement. Hospitalization occurred in 25% (95% CI: 19-30%). In studies that reported treatment, corticosteroids were prescribed more frequently (38%; 95% CI: 27-48%) than nonsteroidal anti-inflammatory drugs (28%; 95% CI: 2-53%). Case fatality was 7% (95% CI: 4-11%), but death attributed to TB-IRIS occurred in 2% of cases (95% CI: 1-3%).

Keywords: HIV; IRIS; antiretroviral therapy; immune reconstitution inflammatory syndrome; paradoxical; tuberculosis.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / drug therapy
  • Immune Reconstitution Inflammatory Syndrome / epidemiology
  • Immune Reconstitution Inflammatory Syndrome / pathology*
  • Incidence
  • Middle Aged
  • Mortality
  • Survival Analysis
  • Treatment Outcome
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology
  • Tuberculosis / immunology*
  • Tuberculosis / pathology*
  • Young Adult

Substances

  • Anti-HIV Agents
  • Anti-Inflammatory Agents